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Statement of translational relevance: This is the first study to report long-term responders to a 
poly(ADP-ribose) polymerase (PARP) inhibitor, with response durations of >2 years, in the 
context of platinum-sensitive, high-grade serous ovarian cancer. Based on extensive molecular 
profiling, the durable long-term responses were multifactorial and driven by germline and 
somatic BRCA1/2 mutations. The majority of patients in the long-term responders group 
harboured homologous recombination repair deficiency, with particular enrichment for 
mutations in BRCA2, compared with short-term responders. This pilot study also highlights 
potential non-BRCA1/2-mutated patients who demonstrated durable clinical benefit with the 
PARP inhibitor olaparib and, together with an ongoing larger cohort study (NCT02489058), 
seeks to identify additional molecular characteristics that can predict susceptibility to olaparib. 
Further investigation may allow outreach to more patients for treatment with olaparib. 
Statement of translational evidence word count: 125/150  
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ABSTRACT  
Purpose: Maintenance therapy with olaparib has improved progression-free survival in 
women with high-grade serous ovarian cancer (HGSOC), particularly those harboring BRCA1/2 
mutations. The objective of this study was to characterize long-term (LT) versus short-term (ST) 
responders to olaparib.   
Design: A comparative molecular analysis of Study 19 (NCT00753545), a randomized 
Phase II trial assessing olaparib maintenance after response to platinum-based chemotherapy in 
HGSOC, was conducted. LT response was defined as response to olaparib/placebo >2 years, ST 
as <3 months. Molecular analyses included germline BRCA1/2 status, three-biomarker 
homologous recombination deficiency (HRD) score, BRCA1 methylation, and mutational 
profiling. Another olaparib maintenance study (Study 41; NCT01081951) was used as an 
additional cohort. 
Results: 37 LT (32 olaparib) and 61 ST (21 olaparib) patients were identified. Treatment 
was significantly associated with outcome (P<0.0001), with more LT patients on olaparib 
(60.4%) than placebo (11.1%). Long-term sensitivity to olaparib correlated with complete 
response to chemotherapy (P<0.05). In the olaparib LT group, 244 genetic alterations were 
detected, with TP53, BRCA1 and BRCA2 mutations being the commonest (90%, 25% and 35%, 
respectively). BRCA2 mutations were enriched among the LT responders. BRCA methylation 
was not associated with response duration. High Myriad HRD score (>42) and/or BRCA1/2 
mutation was associated with LT response to olaparib. Study 41 confirmed the correlation of LT 
response with olaparib and BRCA1/2 mutation. 
Conclusions: Findings show that LT response to olaparib may be multifactorial and 
correlated with homologous recombination repair deficiency, particularly BRCA1/2 defects. The 
type of BRCA1/2 mutation warrants further investigation. 
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INTRODUCTION 
 Epithelial ovarian cancer remains the leading cause of death from gynecologic 
malignancies, with high-grade serous ovarian cancer (HGSOC) the most common histological 
subtype (1). Following cytoreductive surgery and platinum-based chemotherapy, ~70% of 
HGSOC patients relapse despite an initial response to therapy (2). Given the practical certainty 
of recurrence in relapsed HGSOC, a maintenance approach was proposed to delay subsequent 
progression via continuation of treatment beyond cytotoxic chemotherapy. The poly(ADP-ribose) 
polymerase inhibitor (PARPi) olaparib (Lynparza™) is the first validated molecularly targeted 
agent for HGSOC. Ledermann et al demonstrated the benefit of maintenance olaparib after 
response to platinum-based chemotherapy in women with HGSOC recurrence (NCT00753545) 
(3). Patients were randomized to placebo or olaparib, introduced within 8 weeks of completion 
of the last dose of platinum-based chemotherapy and maintained until progression. Olaparib 
maintenance was associated with significantly longer progression-free survival (PFS; median 8.4 
vs 4.8 months; hazard ratio [HR] 0.35; 95% confidence interval [CI] 0.25 to 0.49; P<0.001; data 
maturity 58%). Patients with a BRCA1 mutation (BRCA1m) or a BRCA2 mutation (BRCA2m) 
had significantly greater PFS benefit with olaparib maintenance than those receiving placebo 
(median 11.2 vs 4.3 months; HR 0.18; 95% CI 0.10 to 0.31; P<0.0001; data maturity 52%) (4). 
Overall survival improved by 3 months, which was not significant; possibly because of post-trial 
cross-over whereby 22.6% of placebo patients received PARPi in subsequent clinical trials 
following progression on placebo. Olaparib is now approved in Europe, Australia and Canada for 
the maintenance treatment of women with relapsed, BRCA1/2m-positive (germline or somatic) 
HGSOC who have had complete or partial response to platinum-based chemotherapy (5). 
Olaparib is also approved in the USA for monotherapy in patients with germline BRCA1/2m 
advanced HGSOC who have been treated with ≥3 prior lines of chemotherapy (6). Proteins 
encoded by the BRCA1/2 genes are crucial effectors of double-strand-break DNA repair (7); as a 
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result, BRCA1/2m carriers are known to be highly responsive to DNA-damaging agents, 
including platinum-based chemotherapies (8, 9) and PARPi (8), although mechanisms of action 
and resistance to PARPi are not fully understood (10). Other than deleterious BRCA1m or 
BRCA2m, there are no predictive biomarkers for sensitivity to olaparib. Data from The Cancer 
Genome Atlas (TCGA) and functional studies indicate that approximately half of HGSOC are 
homologous recombination repair (HR) defective (11-13). PARP is involved in the repair of 
single-strand DNA breaks, and its inhibition can result in replication-associated double-strand 
breaks. Such HR-deficient cells as those found in BRCA1/2-mutated tumors, whether repaired 
via error-prone pathways or persistent without repair, cause further genetic instability and can 
lead to cell death (14).  
We hypothesize that studying HGSOC patients with prolonged response to olaparib may 
identify additional biomarkers of response beyond BRCA1/2m. The objective of this study was to 
identify and characterize long-term responders to olaparib maintenance in comparison with 
short-term responders in terms of clinical and molecular profile to pinpoint additional markers of 
response and explore potential resistance factors.   
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METHODS 
Patient population 
We investigated the molecular and clinical characteristics of long- and short-term 
responders randomized to maintenance olaparib or placebo in the phase II, randomized, double-
blind study of olaparib in patients with platinum-sensitive relapsed high-grade serous ovarian 
cancer following treatment with ≥2 lines of platinum-based chemotherapy (NCT00753545; 
Study 19) (3). This trial enrolled 265 patients, with 136 patients assigned to olaparib and 129 to 
placebo. Given that the greatest PFS benefit was at 11.2 months, we defined long-term (LT) 
responders, whatever their BRCA1/2 status, as having a double PFS benefit, i.e. of >2 years. 
Short-term (ST) responders were defined as having PFS of <3 months, given the PFS observed 
in the placebo group of 4.8 months.  
A second comparison/confirmation cohort from the open-label, randomized, phase II 
study of olaparib/carboplatin/paclitaxel with olaparib maintenance versus 
carboplatin/paclitaxel/observation in patients with platinum-sensitive recurrent HGSOC 
(NCT01081951; Study 41) was evaluated (15). In the combination phase, 156 patients were 
treated (81 in the olaparib-plus-chemotherapy group and 75 in the chemotherapy-alone group) 
and 121 continued to maintenance or no further treatment (66 in the olaparib-plus-chemotherapy 
group and 55 in the chemotherapy-alone group). Given that patients in this study received 
olaparib with chemotherapy, the ST responders were defined as patients with PFS of <6 months, 
taking into account the time over which olaparib was administered with chemotherapy to assess 
the maintenance period.  
 
Data collection  
Clinical trial data were prospectively obtained for all treated patients (Table 1) and 
archival tumor specimens, predominantly taken at the time of initial diagnosis, from patients who 
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consented to further use of their specimens. Previously performed germline BRCA1/2 testing 
(Myriad Genetics®) results were obtained.  
 
Molecular investigations 
Assessment of somatic BRCA1/2 mutations (Myriad® tumor testing and Foundation 
Medicine®), determination of the three-biomarker HR deficiency (HRD) score (myChoice® HRD 
test, Myriad Genetics) (16), and BRCA1 methylation (Myriad tumor testing) were conducted (17). 
HRD scores were determined using an assay that calculates scores for whole-genome tumor loss 
of heterozygosity (LOH), telomeric allelic imbalance (TAI) and large-scale state transition (LST). 
The HRD score is the sum of the three scores, where >42 is a predefined threshold validated as a 
high HRD score (16). The Methyl-Profiler DNA Methylation PCR Assay System 
(SABiosciences, Valencia, CA, USA) was used to quantify methylation levels, with a used 
quantitative cut-off of promoter methylation of >10%. HR deficiency status was determined on 
the basis of the combination of the dichotomized HRD score using the predefined HRD 
threshold and tumor BRCA1/2 status (scored as mutated if deleterious or suspected deleterious 
mutations in germline or somatic BRCA1/2 were present). Therefore, HR deficiency was defined 
as a high HRD score (>42) and/or BRCA1/2 mutated tumor (16). 
Mutational profile determined by the Foundation Medicine T5 panel (entire coding 
sequence of 287 cancer-related genes plus select introns from 27 genes) and other genetic 
alterations (deletions and functional rearrangements) were assessed for archival tumor tissue (18). 
Classification of TP53 mutations (TP53m) was determined using the WHO International Agency 
for Research on Cancer Database. 
  
Pathology review 
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Pathology review for tumor cell content was performed for all patients with molecular 
analyses, whereas pathology review of histological subtype by an expert pathologist in 
gynecologic cancer, blinded to cohort or outcome, was only performed for patients with 
remaining tissue.   
  
Statistical analysis 
Descriptive analyses from all LT and ST responders to olaparib/placebo were assessed 
for statistical significance. Fisher’s exact or chi-squared tests were used to test for associations 
between individual explanatory variables and response duration (long vs short term) as 
appropriate. SPSS and Excel were used for all analyses. Given the exploratory data analysis, no 
type 1 error correction was performed. 
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RESULTS   
Clinical data 
Data were collected from 265 total patients on study for the patients with LT and ST 
responses to olaparib therapy or placebo as part of Study 19. Thirty-seven patients were 
identified as LT responders, of whom 32 (86.5%) had received olaparib. Of the 61 ST patients 
identified, 21 (34.4%) had received olaparib. The main characteristics are summarized in Table 1 
and Table 2. LT responders on olaparib (32 patients) had a median of three prior lines of therapy, 
with one-third having relapsed within 6–12 months of their penultimate platinum-based 
chemotherapy. Of the LT responders on olaparib, 44% (14/32) had partial responses to their 
most recent platinum-based chemotherapy, with residual disease evident at the time of olaparib 
maintenance (Table 1). The other 18 of 32 (56%) LT responders on olaparib had complete 
response to the most recent platinum-based chemotherapy, in comparison with only five of 21 
(24%) olaparib ST responders (Table 1). Complete response to platinum-based chemotherapy at 
the time of olaparib maintenance was associated with LT response to olaparib (P=0.026, 
univariate analysis). The treatment-free interval following the penultimate platinum-based 
chemotherapy did not correlate with LT response (Supplementary Table 1). Sixty-five of 98 
archival tumour samples (37 LT and 61 ST) were from primary tumours and nine of 98 were 
from metastases (this information was unavailable for the other 24 patients). 
Receipt of olaparib over placebo was significantly associated with LT 
response (P<0.0001; 32/53, 60.4% vs 5/45, 11.1%). More patients treated with olaparib were LT 
than ST responders (P=0.052).  
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Molecular analysis 
BRCA1/2 status (germline and somatic) 
From the LT responders, 27/37 (73%) had loss-of-function mutations in BRCA1/2. 
Among the 32 LT olaparib responders, BRCA1m and BRCA2m were found in 10 and 13 patients, 
respectively, with one patient showing deleterious mutations in both BRCA1 and BRCA2 (Table 
2 and Table 3). All five LT responders receiving placebo were BRCA1/2m positive (Table 2). A 
greater number of BRCA1/2m was found in LT responders compared with ST responders (Table 
3). In contrast, among the 21 olaparib ST responders, 10 were found to carry a deleterious 
BRCA1/2m (7 of 10 were in BRCA1; Table 2 and Table 3).  
We further analyzed the type and location of BRCA1/2m in the olaparib cohort between 
LT and ST responders (Figure 1 and Supplementary Figure 1). Of the 17 patients on olaparib 
who had BRCA1m (LT and ST), nine had founder mutations (E23fs* or Q1756fs*), whereas 
only one patient had a founder BRCA2m (S1982fs*; ST responder group). Interestingly, among 
patients on olaparib, mutations in the DNA-binding domains of BRCA1 (n=1) or BRCA2 (n=4) 
were only seen in the LT responder group.  
BRCA1 methylation status was available for 27/37 (73%) LT responders, all of whom 
were negative. In contrast BRCA1 methylation status was available for 42/61 (69%) ST 
responders, eight of whom (19%) had BRCA1 methylation. Methylation of BRCA1 was not 
associated with LT olaparib response.  
 
Homologous recombination repair deficiency  
No significant difference was seen between LT and ST responders according to the HRD 
score (Table 3). Most of the patients enrolled in the study were characterized by HR-deficient 
status (81% of the LT and ST on olaparib). Among data available for 26 of the 32 (81%) LT 
responders on olaparib, 25 patients (96%) had HR deficiency, in contrast to 76% of the ST 
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olaparib responders (Table 3). Of the 21 patients with high HRD score in the LT responder group, 
three were BRCA1/2 wild type. Of the nine ST patients with a high HRD score, two (22%) were 
BRCA1/2 negative in the ST responder group. However, a significant number of HRD scores are 
missing for the BRCA1/2 wild-type group (Table 2). 
Taking together high HRD score (>42) and/or BRCA1/2 mutated tumor, there was a trend 
towards HR deficiency in LT versus ST responders, with 96% of LT responders and only 76% of 
ST responders showing HR deficiency (P=0.07). 
 
Next-generation-sequencing analysis 
Next-generation sequencing was performed on archival tumor DNA from 44 patients (28 
[87%] LT and 16 [76%] ST responders on olaparib). From 44 patients, over 600 identified 
alterations were classified by type and likely functional significance by Foundation Medicine 
(Supplementary Table 2). A total of 242 likely functional generic alterations in 99 genes were 
found, with TP53, BRCA1 and BRCA2 mutations being the most common (89%, 34% and 36% 
of patients, respectively; Figure 2 and Supplementary Table 2).  
TP53 signalling was considered aberrant in most cases (90%), as expected for the 
HGSOC histology subtype (27 of 28 patients with available data analyzed in the LT responder 
group, 12 of 16 in the ST responder group; Supplementary Figure 1). The patient with no TP53m 
in the LT responder group had pathology reviewed and HGSOC confirmed. Of the four patients 
with no TP53m in the ST responder group, two had confirmed HGSOC. Other types of 
mutations and gene amplifications were observed, particularly in genes encoding proteins 
involved in DNA repair and damage response, regulation of cell cycle, apoptosis, and 
MAPK/PI3K signalling (Figure 2 and Supplementary Table 2). Furthermore, four patients had 
alterations in PTEN (2 homozygous deletions, 1 somatic variant and 1 functional intergenic 
truncation), all of whom were LT responders on olaparib. These PTEN alterations co-occurred 
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with BRCA1/2 mutation for three of the patients, only one LT patient had a PTEN mutation in 
the absence of a BRCA1/2 mutation. In contrast, no PTEN alterations were seen in the ST 
responder group (Supplementary Table 3). Interestingly, three patients randomized to the 
placebo arm had PTEN alterations and were ST responders (Supplementary Table 3). 
 
Validation cohort 
LT and ST responders from Study 41 were identified and analyzed (Figure 3 and 
Supplementary Table 4). In total, 19 LT responders were identified and all were in the olaparib 
arm. Olaparib maintenance was also significantly associated with LT responders (P<0.0001). 
BRCA1/2m was statistically correlated with LT response to olaparib (Supplementary Table 4). 
BRCA1m and BRCA2m were observed in six and five LT responders, respectively. The 11 ST 
patients were all BRCA1/2 wild-type.  
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DISCUSSION 
There are limited data describing ovarian cancer patients who experience prolonged 
benefit from PARP inhibition, other than evidence for the role played by deleterious mutations in 
BRCA1/2. Defective DNA repair via homologous recombination repair deficiency is a 
fundamental vulnerability in HGSOC and can be exploited with PARPi, such as olaparib, by 
induction of cancer-specific synthetic lethality (19). Examination of broader clinical and 
molecular data of extreme responders may uncover potential biomarkers of response (20). We 
identified LT and ST responders to PARPi from women with HGSOC entered into two olaparib 
maintenance trials, Studies 19 and 41, and have molecularly characterized these exceptional 
responders. We found that 32 and 19 patients with recurrent platinum-sensitive HGSOC 
achieved LT (defined as >2 years) response to olaparib maintenance as part of the studies, 
respectively. Germline and somatic BRCA1/2m were observed to be associated with LT response 
to olaparib, with an enrichment of BRCA2m in the LT olaparib responders, compared with the 
frequency of BRCA1m and BRCA2m in HGSOC detected at the start of the trial and the 
BRCA1/2 ratio observed in the general population (21). Our finding is in agreement with data 
suggesting differences in outcome and response to therapy between BRCA1 and BRCA2 
genotypes (22). Previous studies have shown that BRCA2m is associated with prolonged survival 
in invasive epithelial ovarian cancer (23). In 2012, Liu et al showed that the presence of a 
BRCA2m was associated with longer survival and better therapy response than a BRCA1m in 
HGSOC (24). Many LT olaparib responders had a BRCA2m in the RAD51-binding domain, 
described as a frequent site of BRCA2m by TCGA (11), but also in DNA-binding sites (Figure 3). 
As such, mutations in the RAD51 region are expected to attenuate or abolish interactions with 
RAD51, resulting in failure to load RAD51 to DNA-damage sites (24). Our data also suggest that 
silencing of BRCA1 through promoter methylation does not result in improvement in response to 
platinum-based chemotherapy or to sequential chemotherapy and maintenance olaparib therapy, 
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as previously suggested by TCGA and other publications showing a lack of survival benefit and 
correlation with platinum sensitivity (11, 25). 
However, our study did not identify a potential mechanism involved in the small group of 
BRCA1/2 wild-type patients who had a LT benefit to olaparib maintenance, currently not eligible 
for olaparib in clinical practice. Beyond BRCA1/2m, there have been a number of mechanisms of 
HR deficiency described that may correlate with platinum and PARP response (11), and newly 
developed homologous recombination repair panels have assessed several additional novel genes, 
including NBN, MRE11, RAD50, RAD51C, PALB2, BARD1, and BRIP1 (19, 26, 27). Our results 
show that the majority of patients enrolled in the study were HR deficient, a potential enrichment 
due to the selection of HGSOC patients based on platinum-sensitivity recurrence and objective 
response to platinum. The phase II study ARIEL2 investigating rucaparib (another PARPi) 
monotherapy in patients with recurrent platinum-sensitive HGSOC has confirmed BRCA1/2m as 
a biomarker of response, as well as genomic LOH, a potential predictive surrogate marker for 
HR deficiency (28). It was hypothesized that the inability of the cell to perform HR repair leads 
to genomic scarring and LOH, thus enabling the use of high LOH as a signature of HR 
deficiency. However, no data are currently available for LT responders and PARPi progression. 
Recently, the maintenance phase III study of niraparib, another PARPi, showed increased PFS in 
all patients – germline BRCA1/2 patients (the group with greatest benefit), and non-BRCA1/2 
carriers (comprising of both HRD-positive as well as HRD-negative tumors) (29). Eligible 
patients had to have achieved response following 4 to 6 cycles of platinum-based chemotherapy 
with a CA-125 in the normal range or reduced by 90% for at least 7 days; an absence of 
measurable disease greater than 2cm at study commencement. Consistent with our findings, the 
PFS benefit to PARPi is driven by minimal residual disease (complete response prior 
maintenance), BRCA1/2 mutation and HRD-positive tumors, though not exclusively. The current 
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HR deficiency assays available did not completely identify biomarkers involved in response or 
resistance to PARPi.  
Interestingly, four genetic alterations in the PTEN gene were observed, of which three 
were associated with BRCA1/2m in the LT responders on olaparib but none in the ST responder 
group. Moreover, in the placebo arm, three patients with PTEN alterations had disease 
progression within 3 months (Supplementary Table 3). The significance of this finding is not 
clear but warrants further investigation. While many LT responders to olaparib harbor a 
BRCA1/2m, our data show the occurrence of ST responders to olaparib in patients with 
BRCA1/2m. This finding highlights the limitation of the analysis on archival rather than tumor 
tissue at the time of disease progression. There is evidence that in cells deficient in DNA-damage 
repair, such as those with BRCA1/2m, additional mutations can restore function and allow 
effective DNA repair (30). Reversion mutations in BRCA1/2 have been described and associated 
with olaparib and platinum resistance (31), although this effect was supposed to be minimized by 
the selection of patients with response to platinum-based chemotherapy. Understanding 
therapeutic resistance requires comprehensive disease assessment at the specific time of 
therapeutic intervention; timing and treatment strategy are imperative to efficacy. Several 
mechanisms of resistance have been described related to the HR pathway (30). While tumors 
harboring a BRCA1/2m lack the HR repair pathway required for error-free repair of DNA 
double-strand breaks (32), other DNA-repair pathways exist that can become engaged, ultimately 
leading to olaparib resistance but platinum sensitivity, as with non-homologous end-rejoining 
alterations (33, 34). As such, determining the disease- and therapy-specific HR deficiency 
signature is important. Reports on this signature show varying gene lists, and these differences 
are likely attributed to variances in methodologies. Peng et al identified a HR defect gene 
signature that can be used to functionally assess HR status and predict clinical outcomes (27). 
Pennington et al reported that germline and somatic mutations in 13 HR genes predict platinum 
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response and survival in ovarian, fallopian tube and peritoneal carcinomas (26). These signatures 
need prospective validation. 
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CONCLUSION 
This is the first study contrasting LT with ST responders to PARPi in terms of clinical 
and molecular data. Our results show that LT response to olaparib has been observed in 
platinum-sensitive recurrent HGSOC. This durable response may be multifactorial and driven by 
germline and somatic BRCA1/2m. This pilot study warrants a larger cohort to characterize LT 
responders. A study is ongoing to identify LT and ST responders to olaparib and allows for 
additional tumor tissue collection for analysis (NCT02489058).  
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Table 1. Characteristics of patients on olaparib capsule maintenance therapy – Study 19 
 
Clinical status BRCA status 
Treatment duration 
No. of lines of prior 
chemo-therapy 
[median (range)] 
Initial FIGO 
state 
(n pts) 
RECIST at 
baseline (n) 
Platinum 
sensitivity status 
(n) 
BRCAm 
(n=74) 
BRCA WT 
(n=57) 
BRCA 
missing (n=5) 
Olaparib arm 
(n=136) 
       
ST responders:  
<3 months 
21 pts (15%) 
2.8 (2–5) 
1 II/ 
19 III/1 IV 
PR: 16 
CR: 5 
6–12 months: 9 
12 months: 12 
10 (14%) 
7 BRCA1 
9 (16%) 2 
LT responders:  
>2 years 
32 pts 
 (24%) 
2.9 (2–8) 
3 I/II 
25 III/ 3 IV 
Missing: 1 
PR: 14 
CR: 18 
6–12 months: 11 
>12 months: 21 
22 (30%) 
10 BRCA1 
10 (18%) 
 
0 
Placebo arm (n=129)        
ST responders: <3 
months 
40 pts (31%) 
2.8 (2–8) 
3 I/II 
27 III/8 IV 
Missing: 2 
PR: 25 
CR: 15 
6–12 months: 22 
>12 months: 18 
19 (31%) 
16 BRCA1 
18 (30%) 3 
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LT responders: >2 
years 
5 pts 
 (4%) 
2 (2) 5 III 
PR: 1 
CR: 4 
6–12 months: 1 
>12 months: 4 
5 (8%) 
4 BRCA1 
0 0 
CR, complete response; FIGO, International Federation of Gynecology and Obstetrics; LT, long term; ST, short term; PR, partial response; pts, patients; RECIST, Response 
Evaluation Criteria in Solid Tumors; WT, wild type  
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Table 2. Molecular profiling of patients on olaparib and on placebo – Study 19 
 
Olaparib arm 
ST responders LT responders 
All pts 
(n=21) 
HRD 
score 
 ≥42 
 (n=9) 
HRD 
score 
 <42  
(n=4) 
HRD  
score 
missing 
(n=8) 
TP53 
mutations 
(n=12) 
TP53 
WT  
 (n=4) 
TP53 
missing 
(n=5) 
All pts 
(n=32) 
HRD 
score 
 ≥42  
(n=21) 
HRD 
score 
 <42  
(n=3) 
HRD  
score 
missing 
(n=8) 
TP53 
mutations 
(n=27) 
TP53  
WT  
 (n=1) 
TP53 
missing 
(n=4) 
BRCAm 
(n=32) 
10 
(48) 
6 (67) 0 4 (50) 7 (58) 1 (25) 2 (40) 22 (69) 18 (86) 2 (67) 2 (25) 20 (74) 0 2 (50) 
BRCA WT 
(n=19) 
9 (43) 2 (22) 3 (75) 4 (50) 5 (42) 3 (75) 1 (20) 10 (31) 3 (14) 1 (33) 6 (75) 7 (26) 1 (100) 2 (50) 
BRCA 
missing 
(n=2) 
2 (9) 1 (11) 1 (25) – – – 2 (40) – – – – – – – 
 
Placebo arm 
ST responders LT responders 
28 
 
All pts 
(n=40) 
HRD 
score  
≥42 
 (n=18) 
HRD 
score 
<42  
(n=11) 
HRD  
score 
missing
 (n=11) 
TP53 
mutation
s (n=29) 
TP53 
 WT  
(n=1) 
TP53 
missing 
(n=10) 
All pts 
(n=5) 
HRD 
score 
≥42  
(n=4) 
HRD 
score 
 <42  
(n=0) 
HRD 
 score 
missing
 (n=1) 
TP53 
mutations 
(n=4) 
TP53  
WT  
(n=1) 
TP53 
missing  
(n=0) 
BRCAm 
(n=24) 
19 (48) 13 (72) 1 (9) 5 (46) 16 (55) 0 3 (30) 5 (100) 4 (100) – 1 (100) 4 (100) 1 (100) – 
BRCA WT 
(n=18) 
18 (45) 5 (28) 
10 
(91) 
3 (27) 13 (45) 1 (100) 4 (40) 0 0 – 0 0 0 – 
BRCA 
missing 
(n=3) 
3 (7) 0 0 3 (27) 0 0 3 (30) 0 – – – – – – 
Data are number (percentage). Pts, patients; LT, long term; ST, short term; WT, wild type 
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Table 3. Analysis of BRCA1 and BRCA2 mutational frequency in the olaparib arm (unless 
otherwise stated), including total BRCA mutations and mutations stratified by somatic 
mutations – Study 19 
Number of patients with 
each mutation shown 
LT responders  
N=32 
ST responders  
N=21 
P value  
(Fisher’s exact 
test) 
 BRCA status available N= 32 N=19  
BRCA mutation 22b (69%) 10 (53%) 0.2179a 
BRCA1 mutation   10 (45%)   7 (70%) 1.0000a 
BRCA2 mutation   13 (59%)   3 (30%) 0.0631a 
BRCA WT           10 (31%) 9 (47%)  
Unknown/missing  
(excluded from analysis) 
– 2 missing 
 
 
Somatic BRCA mutations 
available 
N=32 N=19  
Olaparib treated (N=53) 6 3  
BRCA mutation 6b (20%) 3 (16%) 1.0000a 
BRCA1 mutation 2 1 1.0000a 
BRCA2 mutation 5 2 0.6909a 
Placebo treated (N=45) 1 3  
BRCA1 methylation status 
available 
N=23 N=14  
Methylated 0 2 (14%)  
Un-methylated 23 (100%) 12 (86%)  
Unknown/missing  9 missing 7 missing  
30 
 
(excluded from 
analysis) 
HRD score available  N=24 N=13  
HRD score (>42) 21 (88%) 9 (69%) 0.2128a 
HRD score (<42) 3 (12%) 4 (31%)  
HR deficiency status 
available 
 N=26  N=17 
 
HR deficient 25 (96%) 13 (76%) 0.0707a 
HR non-deficient 1 (4%) 4 (24%)  
HRD scores are given for LT responders and ST responders, and HR deficiency status is defined as a high HRD 
score and/or presence of a BRCA1/2 mutation. aP value between groups compared with WT; bOne LT responder had 
both BRCA1 and BRCA2 mutations. HRD, homologous recombination repair deficiency; HR, homologous 
recombination repair; LT, long term; ST, short term; WT, wild type 
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FIGURE LEGENDS 
Figure 1. Location of the BRCA1/2 mutation on the BRCA1/2 gene in patients on olaparib – 
Study 19  
Somatic deletion exon 17 (not shown) found in BRCA1 in LT responder group. Large insertion (somatic, now shown) 
and deletion (not shown) found in BRCA2 in ST and LT responder group, respectively. VUS and SNP variants not 
shown 
 
Figure 2. Mutations and other gene alterations in LT and ST responders to olaparib – 
Study 19 
Only events that occurred in at least two patients are shown. Columns represent patients. Dark grey columns are 
samples that failed sequencing or analysis. A total of 51 patients were analyzed (32 LT responders, 19 ST 
responders), but seven failed sequencing; therefore, the molecular profiles of 44 patients are shown. Novel 
rearrangements of unknown significance, short variants of unknown significance, and non-focal lower-level (copy 
number [CN] ≤8) amplifications of genes known to be recurrently amplified in cancer are excluded 
 
Figure 3. Study 41 data showing LT and ST responders to olaparib and placebo, with 
mutations and other gene alterations given for LT and ST responders  
Novel rearrangements of unknown significance, short variants of unknown significance, and non-focal lower-level 
(CN ≤8) amplifications of genes known to be recurrently amplified in cancer are excluded 
  
32 
 
FIGURES 
 
Figure 1. Location of the BRCA1/2 mutation on the BRCA1/2 gene in patients on olaparib 
Somatic deletion exon 17 (not shown) found in BRCA1 in LT responder group. Large insertion (somatic, now shown) 
and deletion (not shown) found in BRCA2 in ST and LT responder group, respectively. VUS and SNP variants not 
shown 
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Figure 2. Mutations and other gene alterations in LT and ST responders to olaparib 
Only events that occurred in at least two patients are shown. Columns represent patients. Dark grey columns are 
samples that failed sequencing or analysis. A total of 51 patients were analyzed (32 LT responders, 19 ST 
responders), but seven failed sequencing; therefore, the molecular profiles of 44 patients are shown. Novel 
rearrangements of unknown significance, short variants of unknown significance, and non-focal lower-level (copy 
number [CN] ≤8) amplifications of genes known to be recurrently amplified in cancer are excluded 
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Figure 3. Study 41 data showing LT and ST responders to olaparib and placebo, with 
mutations and other gene alterations given for LT and ST responders  
Novel rearrangements of unknown significance, short variants of unknown significance, and non-focal lower-level 
(CN ≤8) amplifications of genes known to be recurrently amplified in cancer are excluded 
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